Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings – PRNewswire

HOUSTON, Feb. 16, 2021 /PRNewswire/ --Iterion Therapeutics, Inc. ("Iterion"), a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has raised $17 million USD in a Series B financing led by Lumira Ventures, with the participation of existing investors, including Sant Ventures, as well as new investors Venture Investors, GPG Ventures, and Viva BioInnovator.

Iterion plans to utilize the proceeds from this financing to advance the development of its lead clinical candidate, Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor.Tegavivint is currently being investigated in a Phase 1/2a clinical trial in patients with desmoid tumors, which are rare, non-metastasizing sarcomas that overexpress nuclear beta-catenin. Iterion has received Orphan Drug Designation for Tegavivint to treat desmoid tumors, a disease for which there are no FDA approved therapies.

In addition to desmoid tumors, Iterion is preparing to initiate clinical programs in 2021 to investigate Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. These cancers are often characterized by nuclear beta-catenin overexpression, providing potential high-value target expansions for Tegavivint.

"We envision incredible potential therapeutic benefits associated with Tegavivint, and are excited to support the Iterion team in its exploration of multiple clinical development opportunities for this potentially groundbreaking therapeutic," said Benjamin Rovinski, Ph.D., Managing Director at Lumira Ventures. "2021 is expected to be a pivotal year for Iterion as the company anticipates initiating clinical trials in AML, NSCLC and pediatric cancers, all indications in which nuclear beta-catenin signaling plays a role. By pursuing a novel mechanism of action, we believe Tegavivint has the potential to overcome challenges faced by prior drugs targeting this pathway."

Nuclear beta-catenin is a highly-studied oncology target associated with numerous cancer types. Tegavivint is unique among nuclear beta-catenin inhibitors in that it binds to TBL1 (Transducin Beta-like Protein One), a novel downstream target in the Wnt-signaling pathway. As such, Tegavivint enables silencing of Wnt-pathway gene expression without affecting other necessary Wnt/beta-catenin functions in the cell membrane, thus avoiding toxicity issues common to other drugs in this pathway.

"We are grateful to have the confidence of investors, including Lumira Ventures, Sant Ventures and others, that appreciate Tegavivint's potential to treat a host of cancers," said Rahul Aras, Ph.D., CEO of Iterion."Nuclear beta-catenin has historically been considered an 'undruggable' oncology target with prior inhibitors having been plagued by toxicity issues, greatly limiting their therapeutic use. Research suggests that these toxicity concerns can be negated by targeting TBL1, a novel downstream target in the Wnt-signaling pathway necessary for beta-catenin's oncogenic activity. This is precisely Tegavivint's mechanism of action and why we believe the technology holds such substantial promise."

Dr. Aras continued, "With the Series B funding, Iterion has the potential to significantly expand our clinical footprint through completion of our ongoing desmoid tumor study and initiate clinical trials in 2021 to investigate Tegavivint in AML, NSCLC, and certain pediatric cancers."

About Iterion TherapeuticsIterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear beta-catenin, a historically "undruggable" oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors. Iterion is also pursuing clinical programs in additional cancers where nuclear beta-catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. Iterion is the recipient of an up to $15.9 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information on Iterion, please visit https://iteriontherapeutics.com or follow the Company on Twitter and Linkedin.

Tiberend Strategic Advisors, Inc.Ingrid Mezo (Media)646-604-5150 [emailprotected]

SOURCE Iterion Therapeutics

See more here:
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings - PRNewswire

Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market – BioSpace

Humanized Mouse and Rat Model Market: Introduction

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81403

Key Drivers, Restrains, and Opportunities of Global Humanized Mouse and Rat Model Market

Request for Analysis of COVID-19 Impact on Humanized Mouse and Rat Model Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81403

North America to Capture Major Share of Global Humanized Mouse and Rat Model Market

Pre Book Humanized Mouse and Rat Model Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=81403&ltype=S

Read more information here:

https://www.transparencymarketresearch.com/humanized-mouse-and-rat-model-market.html

Key Players Operating in Global Humanized Mouse and Rat Model Market

The global humanized mouse and rat model market is highly consolidated due to the presence of key players. A large number of manufacturers hold a major share in their respective regions. Growth strategies adopted by leading players are likely to drive the global humanized mouse and rat model market. For instance, in February 2020, Taconic Biosciences, a global pioneer in offering drug discovery animal model solutions, announced that its humanized immune system mice models were presently being developed in Europe. Local manufacturing makes it easier for Europe-based drug discovery researchers to access this vital oncology research instrument.

Ask for Discount :

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=81403

Major players operating in the global humanized mouse and rat model market are listed below:

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit Bhisey Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read more from the original source:
Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market - BioSpace

Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,…

Apoptosis assays marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.10% in the forecast period of 2020 to 2027 and is expected to reach USD 8.80 billion by 2027.

Apoptosis Assays market research report utilizes the graphs and charts which turns it into more visually appealing. This makes available the best way to the users to understand customer and thus increase their satisfaction by answering the needs and expectations. It also helps to see what factors are influencing the business, where the brand is situated, and get the temperature of the market before a product is launched. Once all the market analysis and studies are done, it is time to present them efficiently, so as to onboard everyone and make the right decisions for the business strategy market research reports are the key partners in the matter.

Download Sample PDF Copy of Report + All Related Graphs @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-apoptosis-assays-market

The major players covered in the apoptosis assays market report areMerck Group, Thermo Fisher Scientific, Inc., BD, Bio-Rad Laboratories, Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG, Biotium, Inc., Creative Bioarray, GE Healthcare, Danaher Corporation, Geno Technology Inc, GeneCopoeia, Inc, Bio-Techne, PerkinElmer, Promega, General Electric and BioTek among other domestic and global players.

Segmentation:Global Apoptosis Assays Market

Apoptosis Assays MarketBy Product

(Assay Kits, Reagents, Microplates, Instruments),

Apoptosis Assays Market By Technology

(Flow Cytometry, Cell Imaging & Analysis Systems, Spectrophotometry, Other Detection Technologies),

Apoptosis Assays Market By End User

(Pharmaceutical and Biotechnology Companies, Hospital and Diagnostic Laboratories, Academic and Research Institutes),

Apoptosis Assays Market By Application

(Drug Discovery & Development, Clinical & Diagnostic Applications, Basic Research, Stem Cell Research),

Apoptosis Assays MarketBy Country

(U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa)

Enquire Here Get customization & check discount for report @:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-apoptosis-assays-market

Global Apoptosis Assays Market Drivers & Restraints:

The increasing cell-based research will help in escalating the growth of the apoptosis assays market.

The increasing incidence and prevalence of chronic and infectious diseases, development of apoptosis-modulating drugs, rising funding for cancer research, growing population suffering from chronic and autoimmune diseases are some of the factors expected to drive the growth of the apoptosis assays market in the forecast period of 2020 to 2027.

On the other hand, the growing adoption of apoptosis assays in developing markets will create several opportunities that will lead to the growth of the apoptosis assays market in the above mentioned period.

Lack of skilled personnel for research and development of apoptosis assays will likely to hamper growth of the apoptosis assays market in the above mentioned period.

Table of Contents:

Know More About Apoptosis assays market @https://www.databridgemarketresearch.com/reports/global-apoptosis-assays-market

Key points for analysis

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email:Corporatesales@databridgemarketresearch.com

Follow this link:
Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,...

Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer…

Written by AZoMFeb 16 2021

Dublin, Ireland, 16 February 2021 Tibidabo Scientific Industries Ltd (Tibidabo Scientific), a global leader and supplier of highly differentiated technology for scientific research, aerospace, and industrial markets, has today announced the appointment of John LaViola as its Chief Technology Officer (CTO) and Head of Business Development.

John LaViola

We are honored to welcome John to our team. As a visionary executive, his technology leadership, scientific rigor, and unique insights are well-known throughout the scientific imaging community. Johns appointment comes at an exciting time for our company, as we accelerate technological innovation and expansion of our growing product offering, explained Paul Murtagh, Chairman & Chief Executive Officer at Tibidabo Scientific. In organizations ranging in size and complexity from early stage to global enterprises, John has been managing R&D and Business Development of medical device, scientific, and imaging systems for over 35 years across a broad range of clinical and scientific disciplines. We are looking forward to harnessing his unique skillset across our expanding business.

Mr. LaViola will lead the companys technology vision and strategy, define the future direction of R&D, and oversee our Mergers & Acquisitions execution and integration. Since 2014, John has served as Vice President, Business Development, and in 2018 assumed leadership for Strategic Innovation in Hologic, Inc.s (Nasdaq: HOLX) Breast and Skeletal Health Solutions division. At Hologic, John was responsible for mergers and acquisitions, technology partnerships, and business alliances, as well as product and service innovation strategy in Hologics largest business unit. He led numerous public and private acquisitions, as well as consummated several strategic partnerships. With a lengthy track record of developing and commercializing disruptive innovations, John previously held technology leadership roles as Vice President, R&D from 2008, and as Senior Director, R&D from 2002 at Hologic.

To learn more, please visit http://www.tibidaboscientific.com

Tibidabo Scientific Industries is a global leader and supplier of highly differentiated technology for scientific research, aerospace, and industrial markets. We succeed by helping customers push boundaries in radiobiology, stem cell research, high-performance imaging, radiation detection, surveillance, space exploration and advanced scintillators. With our roots dating back to H2S phosphor screens in radar critical to the Allied defense during World War II, the impact of our products is now felt from the deepest recesses of the earth, to cutting-edge cancer research, and to the far reaches of space. Our collaborative approach and expanding global team enable our customers to make smarter decisions and adopt more effective solutions with ground-breaking technologies. Our philosophy, culture and strategy are guided by the Tibidabo Business Matrix (TBM), a customer, quality, performance and people-oriented management approach with a system of continuous improvement at its core. For further information, please contact Diane Brau, Corporate Communications [emailprotected]

More:
Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer...

How Irish medtech came to thrive – Med-Tech Innovation

Dr Paul Anglim, partnership development lead for EIT Health Ireland-UK, takes a look at how Irelands thriving medtech ecosystem came to be, and why it continues to go from strength to strength.

In understanding Irelands success in medtech, its important to look at how Ireland turned around its manufacturing slump to become a hotspot for nine of the worlds top ten medtech companies.

The origins of its prosperous medtech sector can be traced back to its highly-skilled manufacturing workforce and strategic government support. When the manufacturing industry suffered a downturn in the 1980s, both the Irish government and those running the sites wanted to safeguard and grow the field of manufacturing.

For them, it was time to embed R&D and innovation into medtech.

Making Ireland an attractive place for R&D

Over the next few decades, the Irish governments strategy went beyond offering physical space and taxation grants, with the development of strategic funding agencies and initiatives.

In 2015, the Science Foundation Irelands CRAM Centre for Research in Medical Devices launched Irelands first stem cell manufacturing centre at NUI Galway. With the goal of positioning Ireland as the leader in medical device technology development, the SFI CRAM focusses on delivering affordable transformative solutions for chronic diseases.

Other collaborations between the government, health services and leading universities have further cemented R&D in industry and Irelands healthcare system. Take, for example, the establishment of the Health Innovation Hub Ireland (HIHI) at University College Cork in 2016.

Backed by Enterprise Ireland and the Health Service Executive, the HIHI incorporatespartnering institutes Trinity College Dublin, NUI Galway, Cork Institute of Technology (CIT) andassociated hospital groups to lead on ground-breaking research and harness new healthcare technology, services and products.

The development of clinical and patient-focussed research has paved the way for Ireland to lead on the exchange of technology ideas. According to IDA Ireland,government grant assistance is responsible for 70% of medtech companies in Ireland engaging in research and development activities.

The goal to entrench R&D in the medtech sector is fast becoming a reality.

Industry and government alignment

As the medtech industry looks drive its growth, alignment between governmental agencies and key associations have played a major role in making this possible.

The IDA has made Ireland an attractive place to do business. The break-up of the IDA into three separate organisations in the mid-1990s enabled it to focus on driving high-quality foreign direct investment in Ireland. The US-based medtech company Strykers 2019 investment of more than 200 million in R&D at its Cork facilities is just one example of the IDAs success in brokering landmark deals.

Underscoring its support of industry, the IDA recently announced that it is set to deliver a targeted COVID-19 fund, investing a total of 200 million in medical technologies and pharmaceuticals.

In addition to the IDA, the Irish Medtech Association has been vital in championing the needs of multinationals corporations and SME member companies to the Irish government. Sitting within Ibec, the Irish Medtech Association has a clear grasp on what the actual needs of industry are, how to represent them to governmental bodies and how to ensure Ireland remains a key location for companies to base their operations.

A burgeoning entrepreneurial mindset

There has also been shift in perception on what is means to be an entrepreneur. People want people to be successful. The entrepreneurial mindset is common among university students of today and theres an abundance of university-led programmes to develop innovative ideas.

NUI Galways BioInnovate Fellowship programme has paved the way for a plethora of successful medtech start-ups. Supported by Enterprise Ireland, BioInnovate delivers needs led innovation based on a proven Stanford BioDesign framework, identifying where recommended solutions would have the most impact.

BioInnovate, like other university-led fellowships, is physically housed in the same place as earlier stage programmes, enabling innovators to meet, network and share new ideas.

In these spaces, the entrepreneurial mindset is the norm, and new innovators emerge in Irelands medtech sector.

Ireland as a thriving medtech ecosystem

Taking into account the support from government agencies, industry, clinical and academic institutions, the existence of Irelands 300-plus community of medtech companies can be better understood.

It is in this dynamic environment that EU-backed organisations like EIT Health, a network of leading health innovators, have decided to expand their presence in Ireland.

Read more:
How Irish medtech came to thrive - Med-Tech Innovation

Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,…

According to the new market research report of Index Markets Research, theCell Expansion Market by Product Type(Human cells, Animal cells),by Application (Regenerative Medicine and Stem Cell Research, Cancer and Cell-based Research, Others) and by Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) Global Forecast to 2026. The worldwide Cell Expansion Market size in 2021 is assessed at USD XX.XX billion and is projected to arrive at USD XX.XX billion by 2026, at a CAGR of X.X% from 2021 to 2026.[Get a Free Sample PDF Report to Understand our Report Before You Purchase]The report helps in evaluating the current situation of the worldwide Cell Expansion market scene and henceforth supporting the customers in settling on educated choices identified with their business systems and speculations. The report likewise subtleties a solid appraisal of the effect of the COVID-19 pandemic on the Cell Expansion market and has a record of systems and strategies embraced by significant parts in the Cell Expansion market to guarantee most extreme profitability and productivity.

What does the Report Include?

The market report incorporatessubjective and quantitative analysisof a few factors, for example, thekey driversand restrictions that will affect development. Furthermore, the report gives bits of knowledge into theterritorial analysisthat covers various areas, adding to the development of the market. It incorporates thecompetitive landscapethat includes the main organizations and the reception of procedures to declare associations, present new products, and team up to additionally add to the development of the market somewhere in the range of 2021 and 2026. In addition, the analysis investigator has embraced a few explorationstrategies to separate data about the latest thingsand industry improvements that will drive the market development during the forecast period.

Key benefits for stakeholders

Porters five powers investigation helps the capability of the purchasers and providers and the serious situation of the industry for strategy building. It diagrams the latest things and future estimations of the market from 2021 to 2026 to comprehend the predominant chances and potential venture pockets. The significant nations in the area have been planned by their individual income commitment to the regional market. The key drivers, restrictions, and opportunities and their definite effect analysis are clarified in the investigation. The profiles of vital participants alongside their key vital advancements are enrolled in the report.

Browse Detailed Research report @https://www.indexmarketsresearch.com/report/global-cell-expansion-market-8/471256/

What Are The Market Factors That Are Explained In The Report?

Key Strategic Developments:The investigation additionally incorporates the key advancements of the market, involving R&D, new product dispatch, M&A, arrangements, coordinated efforts, organizations, joint endeavors, and provincial development of the main rivals working in the market on a worldwide and local scale.

Analytical Tools:The Cell Expansion Market Report incorporates the precisely contemplated and surveyed information of the key business players and their extension in the market by methods for various insightful instruments. The logical devices, for example, Porters five powers investigation, SWOT examination, plausibility study, and speculation return examination have been utilized to dissect the development of the central participants working on the lookout.

Key Market Features:The report assessed key market highlights, including income, value, limit, limit usage rate, net, creation, creation rate, utilization, import/trade, supply/request, cost, piece of the pie, CAGR, and gross edge. Also, the investigation offers an extensive investigation of the key market elements and their most recent patterns, alongside appropriate market portions and sub-fragments.

Detailed Table of Content:

1. Introduction Research Scope Market Segmentation Research Methodology Definitions and Assumptions 2. Executive Summary 3. Market Dynamics Market Drivers Market Restraints Market Opportunities 4. Key Insights Key Emerging Trends: For Major Countries Key Developments: Capacity Expansions, Acquisitions, Partnerships, etc. Latest Technological Advancement Insights on Regulatory Scenario Porters Five Forces Analysis 5. Qualitative Insights on Impact of COVID-19 on Global Cell Expansion Market Supply Chain Analysis & Challenges due to Covid-19 Steps taken by Government / Companies to Overcome this Impact Potential Challenges and Opportunities due to COVID-19 Outbreak 6. Global Cell Expansion Market Analysis, Insights and Forecast, 2016-2027 Key Findings / Summary Market Size Estimates and Forecast -By Product (Value and Volume) -By Application (Value and Volume) -By Region (Value and Volume) North America Europe Asia Pacific Latin America Middle East & Africa

TOC Continued!https://www.indexmarketsresearch.com/report/global-cell-expansion-market-8/471256/#toc

Why us?

We encourage you with a urgent detailed knowledge report on the Cell Expansion market. We structure the reports to build your work process effectiveness. Descriptive graphs, logical outlines, and more scientific instruments to give the customers more authentic information in successful yet easy to grasp illustrations. We give you a report that teaches you on the difficulties and issues of the Cell Expansion market and gives you information expected to beat those issues and expand your development potential.

Contact Us On: Phone:+1-202-888-3519 Email:sales@indexmarketsresearch.com Web:www.indexmarketsresearch.com

Link:
Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,...

The PRP Alternative to Knee and Other Surgeries – Sahuarita Sun

Last month we talked about using hyaluronic acid (HA) injections as an alternative to knee replacement surgery. Another alternative to knee replacement is platelet rich plasma, known simply as PRP.

PRP promotes natural healing.

Steroid injections have been one of the standard treatments used as an alternative to knee surgery. But steroids have limitations in how often they can be used, and may not work well for long-term results.

PRP uses the patients own blood components. After blood is drawn, it is placed into a centrifuge, which spins to isolate the platelets. The PRP is then injected into the affected area. The concentrated PRP promotes healing of the injured or inflamed area. Relief begins within a few weeks of the injection, and pain decreases even more as the healing continues.

In addition to being a viable alternative to knee surgery, PRP is effective for rotator cuff issues, pelvic pain and instability, tennis elbow, tendonitis, muscle strains and more.

Now at affordable prices.

Insurance may or may not cover PRP, but it is now affordable enough for most patients to pay for PRP on their own.

For more information, call Pima Orthopedics at 520-624-0888 and ask about the Non-Surgical Knee Relief Program at our Tucson and Green Valley offices.

See the original post:
The PRP Alternative to Knee and Other Surgeries - Sahuarita Sun

Platelet Rich Plasma Market: Applications, Business Trends by Size 2021: Growth Statistics and Key Players Insights by Types, and Development Analysis…

The rising prevalence of the arthritis is augmenting the demand of the blood products, which is ultimately helping the growth of the platelet-rich plasma market.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999558

Key Market Trends:

Pure PRP Segment by Type is Expected to Hold the Largest Market Share

The pure PRP segment of the global platelet rich plasma market is believed to have the largest market share.

The prime factor responsible for the growth of this segment is the significance of this type of platelet plasma for the person. Pure PRP has an edge over traditional PRP, as it requires a two-step concentration process that helps in eliminating unwanted red blood cells (RBCs) and neutrophils. RBCs (that have no therapeutic effects for regeneration) can create a more viscous solution that can be more painful when injected. Neutrophils, a type of white blood cell, have inflammatory components that may increase pain and inflammation post-treatment.

Pure PRP helps the stem cells and regenerative cells in the repair and in rebuilding the damaged tissue. This ultimately speeds up the healing process and reduces pain. In addition, it promotes increased strength and improves the overall function. Therefore, owing to the contribution of pure PRP in the healing process and the rising use of it as a blood product, the segment is expected to dominate the market in the coming future.

North America Dominates the Market and is Expected to Continue the Same Trend for Next Few Years

North America currently dominates the platelet-rich plasma market and is expected to continue its stronghold for a few more years. The United States is a major market, and this is mainly due to the US governments initiatives to develop blood products. In addition, the emergence and adoption of novel technologies are going to help the market in a positive manner.

Reasons to Purchase this Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999558

Key questions answered in the report:

Detailed TOC of Platelet Rich Plasma Market Segmented by Geography Growth, Trend, and Forecast:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Incidences of Sports Injuries 4.2.2 Increasing Number of Androgenic Alopecia Patients 4.2.3 Growing Use of Platelet-rich Plasma in Various Therapeutic Areas 4.2.4 Rising Prevalence of Arthritis 4.3 Market Restraints 4.3.1 Stringent Regulatory Policies 4.3.2 High Prices of Plasma Therapy 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Type 5.1.1 Pure PRP 5.1.2 Leukocyte-rich PRP 5.1.3 Pure Platelet-rich Fibrin 5.1.4 Leukocyte-rich Fibrin 5.2 By Source 5.2.1 Autologous 5.2.2 Allogenic 5.3 By Application 5.3.1 Orthopedic 5.3.1.1 Arthritis 5.3.1.2 Chronic Tendinitis 5.3.1.3 Bone Repair and Regeneration 5.3.2 Dermatology 5.3.2.1 Androgenic Alopecia 5.3.2.2 Plastic Surgery 5.3.2.3 Cardiac Muscle Injury 5.3.2.4 Dental 5.3.2.5 Nerve Injury 5.3.2.6 Other Applications 5.3.3 By End User 5.3.3.1 Hospitals and Clinics 5.3.3.2 Research Institutes 5.3.3.3 Other End Users 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 Australia 5.4.3.5 South Korea 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East & Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East & Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Bio Product Laboratory Ltd (BPL) 6.1.2 Biolife Plasma Services 6.1.3 Biotest AG 6.1.4 Cambryn Biologics LLC 6.1.5 China Biologic Products Inc. 6.1.6 CSL Ltd 6.1.7 Grifols International SA 6.1.8 Kedrion SpA 6.1.9 LFB SA 6.1.10 Octapharma AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Folding Box Board Market Size and Share Analysis 2020: with Covid-19 Impact on Global Business Growth, Forthcoming Developments Forecast to 2026 | Industry Research.co

Ultra-High Strength Steel Market Growth Rate and Business Share 2020: Global Industry Current Trends, Top Companies, Sales and Drivers Analysis Research Report to 2026 | Industry Research.co

Paper Processing Resins Market Share Value Analysis with Key Technologies 2021 Market Dynamics of Key Players, Global Opportunities, Demand Status Forecast till 2026

Lactose-free Milk Powders Market Size Report 2021: Covid-19 Impact Analysis with Top Key Players, Global Industry Share, Future Scope, Business Strategies and Demand Forecast to 2026

Data Center Power Market Share and Forecast Analysis 2021-2023 | Latest Developments of Industry, Segmentation, Global Growth Trends and Business Strategies with Covid-19 Impact

Brushless DC Motors Market Size Trends and Vendor Analysis 2021: includes Drivers and Challenges, Value Chain Analysis by Global Share, Scope and Growth Technology Forecast to 2024 Industry Research.co

Swimming Equipment Market- 2020 Growth and Business Prospects, Industry Size Forecast by Share, Revenue, Development Status, Demand by Regions, Market Potentials Analysis till 2026

Laminated Reel Labels Market Share and Size Analysis 2020 Global Industry Segments by Regions, Types and Applications, Future Demand Status, Growth Dynamics with COVID-19 Impact till 2026

Car Leasing Market Growth Analysis 2020 Recent Trends by Regions, Future Demand Status, Size and Share Value Analysis, Boosting Strategies, COVID-19 Impact by 2024

Vaccine Adjuvants Market 2020 by Top Countries Data with Share Analysis, Global Growth Trends, Market Size by Top Players, Geographical Segmentation Forecast to 2024

3D Computer Graphics Software Market Size Analysis 2020 with Business Boosting Technologies, Forthcoming Growth Rate, Top Regions, Key Players and Investments Opportunities Forecast to 2025

High Performance Plastics Market Size and Share Analysis 2020 Global Future Growth Rate, Industry Players, Developments Status, Trends Forecast to 2026 | Industry Research.co

https://neighborwebsj.com/

Link:
Platelet Rich Plasma Market: Applications, Business Trends by Size 2021: Growth Statistics and Key Players Insights by Types, and Development Analysis...

Coping With Cancer Treatment’s Effects on Skin – Curetoday.com

As she walked into Memorial Sloan Kettering Cancer Center, Erin Hazelton was struck by the appearance of the woman in front of her. Hazelton was at the New York, New York, cancer center to begin treatment for stage 2 invasive ductal carcinoma.

I walked into the center right after another woman, and when I heard her give her date of birth (to the receptionist), I realized that she was only a couple of years older than me, but she looked like she was my mothers age, recalled Hazelton, who received her diagnosis in 2018. When you (get a diagnosis) at age 37 (like I did), its scary. So much of my identity was tied up in how I looked. I was terrified.

Although many cancers are unseen, different types of treatment can lead to painful, visible side effects. After starting treatment, Hazelton experienced skin side effects including universal hair loss; facial wrinkles and loss of collagen; melasma (dark/discolored patches) on her face; dry skin; seeping wounds; scars; and radiation tattoos.

In addition to the regular side effects of chemotherapy, which can be devastating to quality of life, newer targeted therapies and immunotherapies have additional side effects of the skin that can be very frequent and very specific, says Dr. Nicole LeBoeuf, a dermatologist at Brigham and Womens Hospital and director of the skin toxicities program at Dana- Farber Cancer Institute in Boston, Massachusetts.

According to LeBoeuf, systemic cancer treatments can generally be grouped into three categories, and the types of side effects patients could experience will depend on the patients treatment regimen and cancer type.

The first category is cytotoxic, or classic, chemotherapy, which most commonly causes side effects including alopecia, or hair loss; painful rashes on the hands and feet; and general rashes elsewhere on the body that can lead to swelling, pain and itchiness.

Hazeltons initial regimen included Adriamycin (doxorubicin), a chemotherapy drug known as the red devil because of its harsh side effects, followed up with Taxol (paclitaxel). I lost all my hair eyelashes, eyebrows, everything and my skin looked like I had aged a good 15 to 20 years toward the end of it, Hazelton says. My cheeks had wrinkles because the collagen wasnt being renewed; I had melasma, which I hadnt expected, that was made worse by the sun.

She also experienced skin-related side effects from radiation and scars from her lumpectomy. My skin started slowly breaking down over the course of my radiation, and at the end of six weeks, I had seeping wounds, Hazelton says. My nipple looked like it was going to separate from my body.

The second category of treatment that can lead to skin side effects are targeted therapies, which are linked to the specific drug used for that patients treatment. The most commonly talked-about skin side effect of targeted therapy is called a papulopustular, or an acne-like, rash from EGFR inhibitors, or drugs that target the epidermal growth factor receptor mutation. This mutation is found in lung cancers, head and neck cancers, some colon cancers and, rarely, in breast cancer, LeBoeuf says. In fact, 85% of patients who are treated with drugs that target that particular genetic mutation will develop that rash.

Another common skin side effect from targeted therapies is hand-foot skin reaction, which causes painful calluses and blisters on pressure points. These blisters can occur from doing very normal activities, LeBoeuf says. Something as simple as going to the grocery store can make a patients feet look like theyve just run a marathon. Someone who works on a keyboard may experience painful blisters on their fingertips when they type.

Severe skin side effects such as these can prevent patients from resuming everyday activities and make them more likely to discontinue their cancer treatment, leading to a worse prognosis.

The third category of treatment leading to skin side effects is immunotherapy, a type of treatment that boosts the bodys natural defenses, or immune system, to fight the cancer. Immunotherapy is a beast because once you unleash the immune system, you can turn on any and all skin diseases that would happen outside the cancer setting. Anything that could possibly happen in the field of dermatology has been triggered by activating the immune system, LeBoeuf says. It is amazing and it is groundbreaking...but it can also lead to autoimmune disease in any organ.

The most common skin-related side effects of immunotherapies include psoriasis, with bumpy red patches covered in white scales; vitiligo, or whitish patches from lost pigment; and lichen planus, an autoimmune disease that can cause swelling and irritation of the skin, hair, nails and mucous membranes.

Sometimes the adverse immune events that are activated through immunotherapy persist after the treatment has ended. Our approach to these side effects is always to try to uncouple the toxicity from the effects of the drug on the cancer, then target the side effects as specifically as possible, LeBoeuf says. This leaves the rest of the immune system intact to fight the cancer.

Given the variety of possible side effects and the degree to which it may affect a given individual, it can be hard for patients to know which ones to expect and how to manage them if they arise during and after treatment.

Dr. Anisha Patel, an associate professor of dermatology at The University of Texas MD Anderson Cancer Center in Houston, recommends that patients follow good hair, skin and nail habits before starting treatment: Moisturize often, avoid perfumed products, and decrease the use of lacquer on your nails, she says.

Patients who have a history of skin conditions prior to their cancer diagnosis are more likely to see worsening during treatment. If you already have eczema, psoriasis, or acne, those things are more likely to be exaggerated, Patel says. If you have a preexisting skin condition, that should be taken care of before your therapy starts, as well.

During treatment, certain practices can help prevent the most common side effects. For example, wearing ice- cold gloves and socks and using scalp cooling treatments to restrict blood vessels reduces the chances of hair loss and hand-foot syndrome.

Patients should also take steps at home to minimize side effects. Wearing sunscreen, avoiding direct sun exposure and wearing a hat when outdoors can prevent photosensitivity side effects, Patel says.

To manage her symptoms, Hazelton applied organic shea butter daily and wore gloves and socks to bed to keep her skin as moisturized as possible. My nails were actually amazing during treatment because I was moisturizing them so religiously, she says. Whatever your skin can drink up during that time that is nontoxic, contains no preservatives and has no scents will help.

For patients who are undergoing targeted therapy or immunotherapy, dealing with side effects can be more complicated. In general, the newer cancer therapies (like immunotherapy) have very specific side effects, which may require specific treatment, Patel says. Patients have to go into it with the mindset that they will have some sort of side effect and ask their treatment team what to expect and what they can do to minimize it.

LeBoeuf recommends that patients seek the advice of a dermatologist, who can work with the medical oncologist to manage skin side effects. Whenever possible, if a specific dermatologic diagnosis can (be) made, then the most appropriate treatment can be instituted as quickly as possible, LeBoeuf says. If you treat the side effect specifically, based on dermatologic literature, then often, patients will recover and can continue their cancer treatment, as well.

Both Patel and LeBoeuf urge that the mental and emotional side effects of treatment-related skin conditions receive as much attention as the physical side effects. Often, patients are embarrassed or they feel like they shouldnt be concerned about a side effect that isnt life-threatening, LeBoeuf says. But the reality is, if a side effect affects your quality of life, increases your stress or changes your course of treatment, it can also affect your ability to fight the cancer. So be open, ask for help and advocate for referrals if you feel you arent getting the treatment you need. Maintaining skin health can also prevent secondary problems such as infections or ulcers and can minimize scarring.

Taking one day at a time helped Hazelton maintain a positive mindset. Thinking Am I going to burn during radiation? or Whats my scar going to look like? doesnt help you mentally. Just approach it as it comes, she says.

Patients might be surprised to learn that there is a silver lining to skin-related side effects: Skin side effects to some of the newer targeted and immune therapies is correlated to having a better tumor response, Patel says. It is correlated to the bodys immune system being revved up to fight the cancer.

Post treatment, patients should be advised about options to help restore the health of their skin, hair and nails. What happens after the treatment isnt talked about as much, Dr. Anthony Rossi, a dermatologist and surgeon specializing in skin cancer, lasers and cosmetic surgery at Memorial Sloan Kettering Cancer Center, says. Radiation can cause chronic changes in the skin; surgery, obviously, leaves a lot of scars, and high-dose steroids can leave stretch marks that last forever.

To combat these side effects, Rossi and his team at Memorial Sloan Kettering are working on what they call restorative oncodermatology, which, he says, aims to restore patients who go through cancer treatment and help them get back the form and function of their skin.

Through the use of treatments such as topical retinoids, topical skincare, chemical peels, lasers, botulinum neurotoxin (such as Botox) and platelet- rich plasma (or PRP) injections an experimental therapy that uses injections of the patients own blood platelets to prompt hair growth Rossi reports that many survivors are seeing life-changing results. There is definitely a cosmetic aspect that people want to improve... but these treatments help with skin functionality and overall quality of life, most importantly, he says.

Hazelton has received chemical peels and laser treatments to reduce her wrinkles and melasma, as well as used over- the-counter eyelash serums to help her hair grow back.

I thought my life was over when I got my diagnosis. I thought I would never look the same or feel the same ... but there are people out there to help you fix these physical things that remind you of your sickness, she says. A lot of people bounce back more than they expect they will. ... Your body really does recover; you just have to give it a chance.

See the original post here:
Coping With Cancer Treatment's Effects on Skin - Curetoday.com

AI project to power the future of stem cell manufacturing – TechCentral.ie

Stem cell images from DeepStain project

Valitacell, CeADAR receive 242,000 from Enterprise Ireland and EU

Print

Read More: AI artifical intelligence CeADAR stem cells Valitacell

A new project to improve stem cell manufacturing using artificial intelligence (AI) could have lasting impacts for the health sector.

The three-year project, entitled DeepStain: Deep Learning for Cell Image Analysis hopes toaccelerate an area of drug development which is at the root of many diseases.

DeepStain is part of a strategic partnership between Irish biotechnology company Valitacell and CeADAR, Irelands Centre for Applied Artificial Intelligence.

The project has received 242,000 funding from Enterprise Ireland and the EU under the Marie Skodowska-Curie Co-Fund Scheme, which is part of the Horizon 2020 Research and Innovation programme.

Stem cells have the potential to treat many conditions including cancer, arthritis, and Crohns disease. Monitoring stem cell quality involves a lot of slow and difficult laboratory work, meaning they can behard to manufacture.

The DeepStain project will use AIto quickly analyse images of stem cells to determine their quality and make stem cell manufacturing more efficient.

The core team is composed of Dr Ricardo Simon Carbajo (CeADAR), Dr Paul Dobson (Valitacell) and Dr PolatGkta(CeADAR & Valitacell), and builds on previous work and interdisciplinary expertise.

AI can massively help to improve the Biopharma value chain, said Dr Ricardo Simon Carbajo, head of innovation & development at CeADAR. In this project, we will be applying the latest techniques in Computer Vision to speed up the process of manufacturing stem cells. We are delighted to partner with Valitacell as they are truly innovating in this area and we can produce a real impact in society.

Working with CeADAR will help Valitacell leverage the power of Deep Learning to create better bioprocess analytical technologies to support stem cell therapy manufacturing, said Dr Paul Dobson, head of data at Valitacell. This will help translate stem cells from being a niche experimental therapy into a treatment available to patients worldwide.

TechCentral Reporters

Read More: AI artifical intelligence CeADAR stem cells Valitacell

View All Events

This course is designed to give you and your team all of the tools you need to lift architecture from a documentation process to a true business capability. All IT architects will benefit from the concepts presented in this course. 16 February, 63 CPD Points, Online

The Certified Data Protection Officer Programme has been designed to equip Data Protection Officers with the necessary skills and competencies to meet and maintain all aspects of data protection compliance. 2 March, 63 CPD Points, Online

Be confident that your organisations policies and procedures are legally compliant with data protection legislation by completing Irelands first certified data protection practitioner programme. 9 March, 31.5 CPD Points, Online

Published by Mediateam Ltd., Ireland technology media leader since 1976, 55 Spruce Ave, Sandyford, Dublin 18, A94 N125.

Privacy & Cookies Policy

Continued here:
AI project to power the future of stem cell manufacturing - TechCentral.ie